› 7dv4

X-ray diffraction
2.38Å resolution

Crystal structure of anti-CTLA-4 VH domain in complex with human CTLA-4

Released:
DOI: 10.2210/pdb7dv4/pdb
PDB entry 7dv4 coloured by chain, front view.
PDB entry 7dv4 coloured by chain, side view.
PDB entry 7dv4 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile.
Gan X, Shan Q, Li H, Janssens R, Shen Y, He Y, Chen F, van Haperen R, Drabek D, Li J, Zhang Y, Zhao J, Qin B, Jheng MJ, Chen V, Wang J, Rong Y, Grosveld F
Proc Natl Acad Sci U S A 119 e2200879119 (2022)
PMID: 35925889

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero tetramer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-225502 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Cytotoxic T-lymphocyte protein 4 Chains: A, C, E, G
Molecule details ›
Chains: A, C, E, G
Length: 118 amino acids
Theoretical weight: 12.67 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli BL21(DE3)
UniProt:
  • Canonical: P16410 (Residues: 36-153; Coverage: 63%)
Gene names: CD152, CTLA4
Sequence domains: Immunoglobulin V-set domain
4003-1(VH) Chains: B, D, F, H
Molecule details ›
Chains: B, D, F, H
Length: 120 amino acids
Theoretical weight: 12.89 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli

Ligands and Environments

1 bound ligand:
Ligand EDO 2 x EDO
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: SSRF BEAMLINE BL17U1
Spacegroup: P212121
Unit cell:
a: 75.591Å b: 110.336Å c: 134.185Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.223 0.221 0.258
Expression systems:
  • Escherichia coli BL21(DE3)
  • Escherichia coli

Quick links

Citations

4 review citations

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.
Tian et al. (2023)
3 more

1 mention without citation

An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile.
Gan et al. (2022)